Related Experiment Video

Updated: Jun 23, 2026

Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

Defective expression and modulation of B7-2/CD86 on B cells in B cell chronic lymphocytic leukemia

Zhen-sheng Dai1, Qin-fen Chen, Hong-zhou Lu

  • 1Department of Infectious Disease, Shanghai Public Health Clinical Center affiliated to Fudan University, Jinshan District, Shanghai, People's Republic of China. zhenshengdai@yahoo.com.cn

International Journal of Hematology
|May 12, 2009
PubMed

Insights

Chronic B cell lymphocytic leukemia (B-CLL) shows lower B7-2 expression, a key costimulatory molecule. Interferon-gamma may enhance immunotherapy by boosting B7-2 expression and T-cell response against B-CLL cells.

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • Chronic B cell lymphocytic leukemia (B-CLL) is characterized by malignant monoclonal B cells that resist clearance.
  • Costimulatory molecules, particularly B7-1 (CD80) and B7-2 (CD86), are crucial for T-cell activation and immune response.
  • Defective costimulatory molecule expression may contribute to immune evasion in B-CLL.

Purpose of the Study:

  • To investigate the expression levels of B7-1 and B7-2 on B cells in patients with B-CLL.
  • To explore the potential of interferon-gamma in modulating B7-2 expression and enhancing anti-leukemia T-cell responses.

Main Methods:

  • Flow cytometry was used to detect B7-1 and B7-2 expression on B cells from B-CLL patients and healthy controls.
  • Interferon-gamma treatment was applied to assess its effect on B7-2 expression and T-cell activation against B-CLL cells.

Main Results:

  • B-CLL patients exhibited significantly lower B7-2 expression on their B cells compared to normal individuals.
  • Interferon-gamma treatment resulted in a slight induction of B7-2 expression.
  • Interferon-gamma also promoted T-cell responses against B-CLL cells.

Conclusions:

  • Defective B7-2 expression is implicated as a pathogenic mechanism in B-CLL.
  • Interferon-gamma demonstrates potential as an immunotherapeutic agent for B-CLL by modulating B7-2 expression and improving T-cell mediated anti-leukemia activity.

More Related Videos

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Related Concept Videos

B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...